

# Melasma: A Step-by-Step Approach Towards a Multimodal Combination Therapy

Wolfgang G Philipp-Dormston<sup>1,2</sup>

<sup>1</sup>Hautzentrum Köln/Cologne Dermatology, Cologne, Germany; <sup>2</sup>Faculty of Health, University of Witten/Herdecke, Witten, Germany

Correspondence: Wolfgang G Philipp-Dormston, Hautzentrum Köln/Cologne Dermatology, Schillingsrotter Str. 39-41, Cologne, 50996, Germany, Tel +49 221 39800 200, Fax +49-221-39800 201, Email wpd@haut-zentrum.com

**Abstract:** Melasma is a common challenge in the field of pigmentary skin disorders, exerting a significant emotional and psychosocial burden on patients. The persistent and recurring nature of melasma complicates its management in routine clinical practice. This comprehensive review outlines a stepwise, practical approach encompassing diagnostic, preventive and therapeutic strategies for the management of melasma. A thorough exploration of aggravating and exacerbating factors, including sun exposure, hormonal imbalances, photosensitizing medication and cosmetics, is essential for a holistic assessment of the disease. With an emphasis on consistent and effective photoprotection, initial topical treatment modalities target the melanin production and/or the transfer of melanosomes to keratinocytes. Topical tyrosine inhibitors emerge as the first choice for reducing and preventing hyperpigmentation, with compounds such as thiamidol or tranexamic acid (TXA) being preferred for their safety profile over hydroquinone (HQ), kojic acid and arbutin. Combination with chemical peels can further enhance the therapeutic efficacy, even in cases with resistant melasma. In more severe cases, laser- and light-based interventions may be considered, but with the caveat of the likelihood of recurrence within 3–6 months. Assisted TXA delivery, via either fractional non-ablative laser or microneedling techniques, can further improve clinical outcomes. In conclusion, an optimal melasma management strategy is a multimodal approach, which includes effective photoprotection and a mix of different topical treatments targeting melanin synthesis, the anti-inflammatory environment, senescence and vascularity. Complementary procedures, such as chemical peels, and laser, light-based or microneedling procedures, with or without TXA, can further expedite melanin clearance in more severely affected instances. Individual discussions with patients regarding treatment expectations, recurrence likelihood and potential side effects are paramount to a comprehensive and successful therapeutic journey.

**Keywords:** melasma, chloasma, hyperpigmentation, melanosis

## Introduction

Melasma (syn. chloasma) presents as distinct, symmetrically patterned, hyperpigmented patches or small spots that occur predominantly on sun-exposed areas of the face. While its predominant location is generally centrofacial, affecting 50–80% of cases, melasma can also manifest on malar and mandibular areas.<sup>1,2</sup> The prevalence of melasma exhibits striking variability across populations and ethnicities, with reported overall prevalence rates ranging from of 1% in the general population to as high as 9–50% in high-risk populations, particularly dark-skinned women (Fitzpatrick phototypes III–IV) in their third and fourth decades of life.<sup>3</sup>

Despite being a common and predominantly benign condition, melasma carries a considerable emotional and psychosocial burden, profoundly affecting the patient's self-esteem and overall quality of life.<sup>4,5</sup> Given its persistence and recurring nature, effectively managing patient expectations and implementing preventive and therapeutic interventions tailored to the severity and underlying pathophysiology are paramount. However, reviews providing a practical treatment pathway for the management of melasma are limited.

This comprehensive review outlines a stepwise, up-to-date practical approach encompassing diagnostic, preventive and therapeutic strategies for the management of melasma to facilitate its management in everyday clinical practice.

## Understanding Pathophysiology and Aggravating Factors

The pathogenesis of melasma is multifactorial and not yet fully understood; various internal and environmental factors can contribute to triggering, maintaining and the relapsing of lesions<sup>6,7</sup> (Table 1). Among these, the most important factors are genetic predisposition, sun exposure and hormonal imbalances, especially as they occur in the context of pregnancy (“mask of pregnancy”) or when taking contraceptives. All of them can significantly increase tyrosinase activity. In addition, chronic inflammatory skin diseases, photosensitizing interventions, drugs or food, liver diseases, ovarian tumors, helminthiasis, and even increased stress can cause melasma.<sup>8</sup>

As a concomitant disease, melasma is more often diagnosed in patients with polycystic ovary syndrome, insulin resistance or thyroid dysfunction. Furthermore, 76% of patients report depressive or stress symptoms, which may, at least partially, be caused by hormonal imbalances as well.<sup>3,9</sup>

**Table 1** Factors Contributing to Melasma Pathogenesis and Diagnostic Work-Up

	<b>Factors Contributing to Melasma Pathogenesis</b>	<b>Anamnesis/Diagnostic Work-Up</b>
<b>Genetic Predisposition</b>	<ul style="list-style-type: none"> <li>Abnormal melanocyte activation</li> <li>Excessive melanogenesis</li> </ul>	Genetic testing is not possible, but typical signs of excessive melanogenesis can be seen in dermoscopy, Wood's lamp and/or reflectance confocal microscopy
<b>Environmental Factors</b>	<ul style="list-style-type: none"> <li>UV radiation</li> </ul>	Sunlight exposure, LED screens, tanning beds, type of sunscreens used (UVA, UVB, etc)
	<ul style="list-style-type: none"> <li>Oxidative stress</li> </ul>	
	<ul style="list-style-type: none"> <li>Solar elastosis and photoaging with extracellular matrix abnormalities</li> </ul>	Phototoxic skin care or make-up products, phototoxic medication, eg St. John's wort products
	<ul style="list-style-type: none"> <li>Phototoxic medication</li> </ul>	
<b>Hormonal Factors</b>	<ul style="list-style-type: none"> <li>Excessive consumption of certain food items</li> </ul>	Copper-containing food, soy products, dairy products, high glycemic index products
	<ul style="list-style-type: none"> <li>Hormonal imbalances</li> </ul>	Pregnancy test, sex hormone status, adrenocorticotropic hormone, cortisol, gynecologist consultation
	<ul style="list-style-type: none"> <li>Polycystic ovary syndrome, ovarian dysfunction and tumors, testicular dysfunction</li> </ul>	
	<ul style="list-style-type: none"> <li>Thyroid disorders</li> </ul>	Thyroid function test
<ul style="list-style-type: none"> <li>Contraceptives and other hormonal therapies</li> </ul>	Contraceptives, diethylstilbestrol, steroids, etc	
<b>Metabolic Disorders</b>	<ul style="list-style-type: none"> <li>Hepatopathies</li> <li>Diabetes mellitus</li> </ul>	Liver function tests, glucose, HbA1c
<b>Proinflammatory Factors</b>	<ul style="list-style-type: none"> <li>Elevated mast cells</li> <li>Increased vascularization</li> </ul>	Blood count/hemogram, inflammatory skin disease
<b>Procedural Factors</b>	<ul style="list-style-type: none"> <li>Basement membrane damage</li> </ul>	Waxing and/or other previous invasive cosmetic or laser skin treatments
<b>Psychological/ Neurological Factors</b>	<ul style="list-style-type: none"> <li>Depression, stress</li> </ul>	Antiepileptic drugs, hydantoin derivatives, chlorpromazine, antidepressants, anxiolytics
	<ul style="list-style-type: none"> <li>Antiepileptic drugs/antidepressants</li> </ul>	
<b>Infections and Parasitic Infestations</b>	<ul style="list-style-type: none"> <li>Malassezia</li> </ul>	Skin culture
	<ul style="list-style-type: none"> <li>Helminthiasis</li> </ul>	Stool examination

**Note:** Data from Pietowska et al (2022)<sup>6</sup> and Bagherani et al (2015).<sup>7</sup>

**Abbreviations:** HbA1c, glycosylated hemoglobin; UVA, ultraviolet A; UVB, ultraviolet B.

## Diagnostic Work-Up


The diagnosis of melasma is primarily based on its clinical presentation; however, it is important to carefully investigate aggravating and triggering factors by obtaining a detailed history of the patient (Table 1) and to rule out other pigmentary disorders, which can mimic melasma.

Familial predisposition is the most important risk factor for melasma, and nearly 300 genes have been identified to be differentially expressed in the skin lesions of melasma. However, no Mendelian pattern of inheritance has been identified yet.<sup>10</sup> The clinical diagnosis can be further confirmed by dermatoscopic examination, showing typical pronounced hyperpigmentation in the pseudo-rete ridges of the skin,<sup>11</sup> or an accentuated, epidermal hyperpigmentation, when using Wood's lamp.<sup>12</sup> Reflectance confocal microscopy (RCM) is another non-invasive technique, showing activated melanocytes and melanophages as well as solar elastosis at a cellular level of resolution.<sup>13,14</sup> Dynamic optical coherence tomography (D-OCT) can be used to study changes in cutaneous blood vessels in melasma before or during treatment.<sup>15</sup> Based on the individual history of the patient, further laboratory tests, such as sex hormones, thyroid and liver function tests, adrenocorticotrophic hormone, cortisol, complete hemogram and stool examination, may be conducted as well (Table 1).

The main differential diagnoses for melasma include ephelides, lentigines, post-inflammatory hyperpigmentation, phototoxic dermatitis, including phytophotodermatitis, and drug-induced pigmentation. In rare cases, lichen planus pigmentosus, discoid lupus erythematosus, erythema dyschromicum perstans, pigmented contact dermatitis, poikiloderma of Civatte, erythromelanosis follicularis faciei, ochronosis, Hori's nevus, argyria, nevus of Ota and macular amyloidosis can also mimic a melasma-like clinical picture.<sup>7</sup>

## Management of Melasma: Practical Guidance

The therapeutic management of melasma is challenging because of its chronic and recurring nature. It includes topical, oral and procedural treatments targeting various aspects of the pathogenesis, including ultraviolet (UV) damage, hyperpigmentation, inflammation and vascularization (Figure 1, Table 2).<sup>16-19</sup>



**Figure 1** The main principles of topical melasma treatment include the inhibition of melanin synthesis pathways.

**Abbreviations:** AHA, alpha-hydroxy acid; DNA, deoxyribonucleic acid; m-RNA, messenger ribonucleic acid.

**Table 2** Overview of Commonly Used Topical or Oral Therapies and Their Mode of Action in Melasma\*

Mode of Action	Substance	Application	Additional Effects	References
Inhibitors of tyrosinase transcription	Retinoids	Topical, oral	Inhibition of UVB-stimulated keratinocytes, reduction of melanosome transfer, increased keratinocyte turnover	[20–31]
Tyrosinase inhibitors	4-n-Butyl resorcinol (Rucinol)	Topical	Inhibitor of TRP-I	[32–39]
	Arbutin	Topical	Inhibitor of DHICA, inhibition of melanosome maturation	[40–42]
	Azelaic acid	Topical	Melanocyte inhibitor	[43–46]
	Cysteamine	Topical	Peroxidase inhibitor, iron and copper chelator; increase in intracellular glutathione; inhibitor of eumelanin synthesis	[47–49]
	Glycolic acid	Topical	Increase in keratinocyte turnover	[25,50–58]
	Hydroquinone	Topical	Peroxidase inhibitor, melanocyte inhibitor, destruction of melanocyte cell membranes	[43,44,46,59–64]
	Kojic acid	Topical		[62–67]
	Thiamidol	Topical		[68–71]
	Tranexamic acid (TXA)	Topical, intradermal, oral	Melanocyte inhibitor, mast cell downregulation, plasmin inhibitor (reducing the amount of arachidonic acid and MSH); reduction of solar elastosis; lowers VEGF and endothelin-I	[72–87]
	Triple combination cream (4% hydroquinone, 0.05% tretinoin and 0.01% fluocinolone acetonide)	Topical	Peroxidase and melanocyte inhibitor; destruction of melanocyte cell membranes, inhibition of UVB-stimulated keratinocytes, inhibition of tyrosinase transcription, reduction of melanosome transfer, increase in keratinocyte turnover; inhibition of recruitment and maturation of mast cells; anti-inflammatory effect	[88–94]
Tyrosinase inhibitor, anti-inflammatory, melanosome inhibitor	Licorice root extract	Topical	Glabridin inhibits tyrosinase, liquiritin reduces UV-induced erythema; anti-inflammatory, melanosome inhibitor	[95–99]
Antioxidants	Ascorbic acid	Topical, oral	Decreases dopaquinone and DHICA oxidation, tyrosinase inhibitor via copper ions, photoprotective	[100–108]
	Pycnogenol	Topical, oral	Anti-inflammatory effect	[109–111]
	Ferulic acid	Topical		[111–113]

Inhibitors of melanosome transfer	Dioic acid	Topical	Intranuclear PPAR agonist	[114]
	Niacinamide	Topical, oral, intravenous	Melanocyte inhibitor, reduction of solar elastosis, anti-inflammatory, anti-aging (stimulation of ceramide production), PAR-2 inhibitor	[115,116]
	Soybean	Topical	Melanosome transfer inhibitor, antioxidant by (isoflavones and serine proteases), pigment attenuating, photoprotective	[117–119]
Increase keratinocyte turnover	Trichloroacetic acid	Topical		[52,120–123]
	Linoleic, alpha-linolenic and oleic acid	Topical	Photoprotective effect	[124]
Inhibitors of recruitment and maturation of mast cells	Corticosteroids	Topical	Anti-inflammatory effect with non-selective inhibition of melanogenesis	[125,126]
Induction of mast cell apoptosis	Calcineurin inhibitors	Topical	Anti-inflammatory effect	[127]
Anti-hormonal substances	Estrogen antagonists or anti-androgenic substances, eg flutamide	Oral, topical	Reduction of the concentrations of MSH and cAMP	[128,129]

**Notes:** Data from Pietowska et al (2022)<sup>6</sup> and Searle et al<sup>18</sup> \*Please see references and additional literature for potential side effects of the different substances. Besides skin irritation, which is common for many active ingredients, and other substance-specific side effects, some substances, eg hydroquinone, arbutin and kojic acid, are suspected of having cancer-promoting effects.

**Abbreviations:** cAMP, cyclic adenosine monophosphate; DHICA, 5,6-dihydroxyindole-2-carboxylic acid; MSH, melanocyte-stimulating hormone; PAR-2, protease-activated receptor 2; PPAR, peroxisome proliferator-activated receptor; TRP-1, tyrosinase-related protein 1; UVB, ultraviolet radiation B; VEGF, vascular endothelial growth factor.

## Tyrosinase Inhibitors


Tyrosinase inhibitors, such as hydroquinone, thiamidol, kojic acid, arbutin, n-butylresorcinol and azelaic acid, competitively inhibit the conversion of 1-3,4-dihydroxyphenylalanine to melanin and are the most targeted dermatocosmetic solution to reduce and prevent hyperpigmentation (Table 2).

Historically, hydroquinone (HQ) 4% as monotherapy, but also in combination with tretinoin and topical steroids (“triple cream”), has been an established topical, first-line treatment over years, but concerns about its side effects (permanent depigmentation, ochronosis, potential risk of cancer due to its metabolites) have prompted the use of potentially safer alternatives and the withdrawal of HQ in many countries.<sup>53,54</sup> Notably, most of the “older” tyrosinase inhibitors were previously tested using an in vitro mushroom tyrosinase model, but showed only limited efficacy in inhibiting the human tyrosinase, while thiamidol 0.2% was identified as being the most effective inhibitor of the human tyrosinase, corresponding to its good clinical efficacy<sup>68–71</sup> (Figure 2).

Besides the inhibition of tyrosinase activity, tranexamic acid (TXA) has additional anti-pigmentary, anti-inflammatory and anti-vascularization properties. It prevents plasminogen binding to keratinocytes, reduces melanocyte-stimulating hormone (MSH), reduces the concentration of arachidonic acid, prostaglandins and leukotrienes in keratinocytes, and is one of the very few methods that inhibits angiogenesis, through the suppression of vascular endothelial growth factor (VEGF) and endothelin-1 (EDN1). TXA can be used orally, topically or via an injection as part of mesotherapy or microneedling.<sup>72–87</sup> Whereas topical TXA 5% was well tolerated in clinical studies, several side effects, including oligomenorrhea, gastrointestinal discomfort, headache and transient skin irritation, were reported with oral TXA; in addition, a possible increased risk of thromboembolism needs to be considered.<sup>6</sup> Therefore, owing to the limited amount of data on the safety of oral TXA, topical or delivery-assisted TXA application should be preferred in melasma patients.

## Retinoids

Topical retinoids, including tretinoin 0.05–0.1%, adapalene, tazarotene, isotretinoin and retinol, regulate the differentiation, proliferation and apoptosis of cells by binding to nuclear receptors (Table 2). They inhibit the transcription of tyrosinase and melanin synthesis and reduce oxidative stress by inhibiting the activation of the matrix metalloproteinase. In addition, they reduce the transfer of melanosomes to keratinocytes and accelerate melanin loss as a result of an



**Figure 2** Inhibition of human tyrosinase by various concentrations of thiamidol, 4-butylresorcinol, kojic acid, arbutin and hydroquinone using an in vitro assay with purified human tyrosinase.

**Notes:** Adapted from Arrowitz C, Schoelermann AM, Mann T, Jiang LI, Weber T, Kolbe L. Effective tyrosinase inhibition by thiamidol results in significant improvement of mild to moderate melasma. *J Invest Dermatol.* 2019;139(8):1691–1698.e6 © 2019, Creative Commons.<sup>69</sup>

increased turnover of keratinocytes and their exfoliative properties. When used in combination, they may enhance the transepidermal penetration of other topical medications.<sup>6,20–31,130–133</sup> However, retinoids are known to be slow-acting substances, and it may take up to 24 weeks to see clinical benefits in melasma.<sup>20</sup> In addition, the risk of secondary hyperpigmentation due to retinoid-induced irritation needs to be considered in melasma.

## Niacinamide

Niacinamide (4%), alone or in combination with retinoic acids, inhibits melanosome transfer to keratinocytes and has been shown to decrease pigmentation in melasma within a period of 8 weeks<sup>115,116,155</sup> (Table 2).

## Antioxidants

Ascorbic acid protects the skin from oxidative stress by neutralizing free radicals, as it is a potent electron donor. In addition, it interacts with the copper ions at the active site of the tyrosinase enzyme and reduces its activity.<sup>100–108</sup> Topical application of ascorbic acid and zinc has been shown to improve skin lesions in melasma, with only very few side effects.<sup>134</sup> Other topical natural antioxidants, such as Korean red ginseng, ferulic acid, and orchid or parsley plant extracts, can improve melasma, as can orally taken antioxidants, such as pycnogenol<sup>111–113,135,136</sup> (Table 2).

## Chemical Peels

Chemical peels are typically used as a second-line treatment procedure in the management of melasma.<sup>19,137–139</sup> Chemical peels can improve melasma by reducing melanin and melanosome transfer owing to their exfoliative properties and by inducing the phagocytosis of melanin. When used in combination with local treatment or laser therapy, they can enhance and accelerate the therapeutic effects, even in the case of resistant melasma.<sup>19,137</sup> However, they should be used with caution, especially in people with darker skin types, because of the risk of post-inflammatory hyperpigmentation.<sup>138,139</sup>

## Laser, Light-Based and Microneedling Techniques

Laser- and light-based therapies, such as intense pulsed light (IPL), Q-switched low-fluency lasers, non-ablative fractional lasers (NAFLs) or picosecond lasers, can accelerate the removal of melanin and lead to more rapid improvement in patients. However, all of these methods are not causative, as they do not have any direct or indirect effect on melanin synthesis. The risk of recurrence and, with some techniques, the risk of post-inflammatory hyperpigmentation or hypopigmentation has to be considered and explicitly explained to patients.<sup>6</sup>

NAFLs may provide a more effective and sustained response, with recurrence after 3–6 months, whereas in IPL or Q-switched laser treatments skin lesions appear usually within 3 months after the procedure. The 1927nm wavelength allows practitioners to treat Fitzpatrick skin types III–VI as well, which is not the case for IPL and Q-switched lasers. Combination with a topical tyrosinase inhibitor, applied before and after the NAFL, can further enhance long-term improvement.<sup>139–144</sup>

Picosecond lasers generate pulses in the picosecond domain, which leads to a mainly photoacoustic-driven melanin fragmentation without causing thermal damage to the surrounding tissues, which may enhance the efficacy and safety properties of this method in treating melasma. The use of picosecond lasers with diffractive lens arrays may, in addition, alleviate related photoaging characteristics, and the effects may be maintained for a longer time.<sup>145–149</sup>

Microneedle radiofrequency (RF) creates microscopic channels to the required depths of the dermis, so that thermal energy can stimulate the production of collagen and elastin. As a result of this controlled skin injury, keratinocyte turnover is accelerated, which leads to increased melanin removal as well as to decreased blood vessel proliferation and restoration of the basement membrane. Owing to its additional benefits on solar elastosis and skin aging, combined with an excellent safety profile, microneedle RF may be beneficial as adjunct melasma therapy.<sup>150</sup>

Topical TXA, alone or in combination with either a fractional CO<sub>2</sub> laser or microneedling, achieved better results than when used alone, but there was no difference between the laser and microneedling techniques.<sup>151,152</sup> Hence, a combination of microneedling or a fractional CO<sub>2</sub> laser with topical TXA 5% may be another treatment alternative for melasma, resulting in better treatment outcomes than the single use of substances or procedures.<sup>151</sup>

## Prevention by Photoprotection

Visible light, especially high-energy visible light (HEVL), and UVA (UVA1) radiation are the main causative triggers for melasma,<sup>148</sup> and the avoidance of and protection against UV radiation and visible light are critical for the sustained control of melasma. Therefore, the use of a broad-spectrum UVA/UVB sunscreen with a high sun protection factor (SPF 30+) and high protection against UVA1 and HEVL all year round should be recommended to all melasma patients. In choosing suitable sunscreen, the combination of broad-spectrum UVA and UVB filters with visible light blockers, such as iron oxide, should be favored, as such combinations showed better results in prevention of melasma flares compared to broad-spectrum UV filters alone.<sup>19,153–155</sup>


## Introducing a Step-by-Step Multimodal Treatment Approach for Melasma

Single treatment approaches are, in general, of limited efficacy for the long-term management of melasma. Hence, a step-by-step, multimodal approach, which includes a mix of treatments and procedures targeting the melanin synthesis pathways, the anti-inflammatory environment, senescence and vascularity, should be used, along with avoidance of exacerbating factors such as UV light and hormonal contraception (Figure 3).<sup>16,17</sup>

In addition to consistent and effective photoprotection, topical treatments that inhibit the melanin synthesis pathway should be considered as first-line therapies for melasma.<sup>6,18</sup> The use of effective and potentially safer topical tyrosinase inhibitors, such as thiamidol or TXA, should be preferred (Figure 4). HQ, arbutin and kojic acid-containing topicals are no longer recommended because of the risk of side effects and the availability of safer alternatives. Combination with topical retinoids and/or niacinamide could be considered to target tyrosinase transcription, melanin synthesis, vascularization and oxidative stress. This can be further enhanced by antioxidants or mesotherapy as adjunct treatment.

Combining topical treatments with chemical peels may further enhance and accelerate therapeutic effects, even in resistant melasma.<sup>19</sup> In more severe and refractory cases, lasers and light-based therapies may be suggested, but patients must be prepared for a high recurrence rate. The combination of fractional CO<sub>2</sub> laser or microneedling techniques with TXA may further improve clinical outcomes.<sup>152</sup>

This comprehensive review is limited by its narrative methodology. It summarizes recent developments in melasma treatment for developing a step-by-step treatment approach for use in everyday clinical practice. It does not replace a systematic review, with a structured assessment and weighting of the individual studies and treatment strategies, and may lack completeness. Recent systematic reviews, however, were considered when available. National and international treatment recommendations are needed to further improve and standardize the management of such a common disease as melasma.



**Figure 3** Management of melasma: a practical approach for a stepwise combination therapy.

**Abbreviations:** TXA, tranexamic acid; NAFL, non-ablative fractional laser; UV, ultraviolet; HEVL, high-energy visible light; SPF, sun protection factor.





**Figure 4** Melasma at baseline (A) and after 12 weeks (B) of treatment with the topical tyrosinase inhibitor thiamidol and subsequent sunscreen use.

**Notes:** Adapted from Philipp-Dormston W G, Vila Echagüe A, Pérez Damonte SH, Riedel J, Filbry A, Warnke K, Lofrano C, Roggenkamp D, Nippel G. Thiamidol containing treatment regimens in facial hyperpigmentation: An international multi-centre approach consisting of a double-blind, controlled, split-face study and of an open-label, real-world study. *Int J Cosmet Sci.* 2020;42(4):377–387. © 2020 Beiersdorf AG. International Journal of Cosmetic Science, published by John Wiley & Sons Ltd on behalf of the Society of Cosmetic Scientists and Société Française de Cosmétologie.<sup>71</sup>

## Conclusion

The treatment of melasma remains challenging owing to its chronic and recurrent nature. Its multifactorial etiology implies the use of a multimodal approach that includes a mix of different topical treatments targeting the melanin synthesis pathways, the anti-inflammatory environment, senescence and vascularity, along with avoidance of exacerbating factors, such as UV light and hormonal contraception. Complementary procedures, including chemical peels, lasers, light-based or microneedling procedures, with or without TXA, can further expedite melanin clearance in more severely affected instances. This comprehensive review outlines a step-by-step clinical approach based on recent evidence encompassing diagnostic, preventive and therapeutic strategies for the management of melasma to facilitate its management in everyday clinical practice. Individual discussions with patients regarding treatment expectations, recurrence likelihood and potential side effects are paramount to a successful therapeutic journey.

## Acknowledgments

The author thanks Dr. med. Michaela Dippel (MD medscript & consult, Wachenheim, Germany) for medical writing support, sponsored by Beiersdorf.

## Disclosure

WGPD has served as a consultant, speaker or investigator for Beiersdorf (Eucerin), Benevi, Eco Elio, Galderma, L'Oréal (La Roche Posay, SkinCeuticals), and Pierre Fabre (Avène). The author reports no other conflicts of interest in this work.

## References

1. Tamega Ade A, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. *J Eur Acad Dermatol Venereol.* 2013;27(2):151–156. doi:10.1111/j.1468-3083.2011.04430.x
2. Mandry Pagan R, Sanchez JL. Mandibular melasma. *PR Health Sci J.* 2000;19(3):231–234.
3. Ogbechie-Godec OA, Elbuluk N. Melasma: an up-to-date comprehensive review. *Dermatol Ther.* 2017;7(3):305–318. doi:10.1007/s13555-017-0194-1

4. Pawaskar MD, Parikh P, Markowski T, McMichael AJ, Feldman SR, Balkrishnan R. Melasma and its impact on health-related quality of life in Hispanic women. *J Dermatol Treat.* 2007;18(1):5–9. doi:10.1080/09546630601028778
5. Platsidaki E, Efstathiou V, Markantoni V, et al. Self-esteem, depression, anxiety and quality of life in patients with melasma living in a sunny Mediterranean area: results from a prospective cross-sectional study. *Dermatol Ther.* 2023;13(5):1127–1136. doi:10.1007/s13555-023-00915-1
6. Piętowska Z, Nowicka D, Szepletowski JC. Understanding melasma - how can pharmacology and cosmetology procedures and prevention help to achieve optimal treatment results? A narrative review. *Int J Environ Res Public Health.* 2022;19(19):12084. doi:10.3390/ijerph191912084
7. Bagherani N, Gianfaldoni S, Smoller BR. An overview on melasma. *J Pigment Disord.* 2015;2(10):218.
8. Sarkar R, Ailawadi P, Garg S. Melasma in men: a review of clinical, etiological, and management issues. *J Clin Aesthetic Dermatol.* 2018;11:53–59.
9. Deshpande SS, Khatu SS, Pardeshi GS, Gokhale NR. Cross-sectional study of psychiatric morbidity in patients with melasma. *Indian J Psychiatry.* 2018;60(3):324–328. doi:10.4103/psychiatry.IndianJPsychiatry\_115\_16
10. Kang HY, Suzuki I, Lee DJ, et al. Transcriptional profiling shows altered expression of Wnt Pathway- and lipid Metabolism-Related genes as well as melanogenesis-related genes in melasma. *J Investig Dermatol.* 2011;131(8):1692–1700. doi:10.1038/jid.2011.109
11. Mishra SN, Dhurat RS, Deshpande DJ, Nayak CS. Diagnostic utility of dermatoscopy in hydroquinone-induced exogenous ochronosis. *Int J Dermatol.* 2013;52(4):413–417. doi:10.1111/j.1365-4632.2011.05305.x
12. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. *Am J Dermatopathol.* 2005;27(2):96–101. PubMed PMID: 15798432. doi:10.1097/01.dad.0000154419.18653.2e
13. Kang HY, Bahadoran P, Suzuki I, et al. In vivo reflectance confocal microscopy detects pigmentary changes in melasma at a cellular level resolution. *Exp Dermatol.* 2010;19(8):e228–e233. doi:10.1111/j.1600-0625.2009.01057.x
14. Farabi B, Khan S, Jamgochian M, Atak MF, Jain M, Rao BK. The role of reflectance confocal microscopy in the diagnosis and management of pigmentary disorders: a review. *J Cosmet Dermatol.* 2023;22(12):3213–3222. doi:10.1111/jocd.15827
15. Pomerantz H, Christman MP, Bloom BS, et al. Dynamic optical coherence tomography of cutaneous blood vessels in melasma and vessel response to oral tranexamic acid. *Lasers Surg Med.* 2021;53(6):861–864. doi:10.1002/lsm.23345
16. Rodrigues M, Pandya AG. Melasma: clinical diagnosis and management options. *Australas J Dermatol.* 2015;56(3):151–163. doi:10.1111/ajd.12290
17. Neagu N, Conforti C, Agozzino M, et al. Melasma treatment: a systematic review. *J Dermatol Treat.* 2022;33(4):1816–1837. doi:10.1080/09546634.2021.1914313
18. Searle T, Al-Niaimi F, Ali FR. The top 10 cosmeceuticals for facial hyperpigmentation. *Dermatol Ther.* 2020;33(6):e14095. doi:10.1111/dth.14095
19. Effron C, Briden ME, Green BA. Enhancing cosmetic outcomes by combining superficial glycolic acid (alpha-hydroxy acid) peels with nonablative lasers, intense pulsed light, and trichloroacetic acid peels. *Cutis.* 2007;79:4–8.
20. Griffiths C, Finkel LJ, Ditre CM, Hamilton TA, Ellis C, Voorhees J. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. *Br J Dermatol.* 1993;129(4):415–421. doi:10.1111/j.1365-2133.1993.tb03169.x
21. Kimbrough-Green CK, Griffiths CE, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. *Arch Dermatol.* 1994;130(6):727–733. doi:10.1001/archderm.1994.01690060057005
22. Green C, Orchard G, Cerio R, et al. A clinicopathological study of the effects of topical retinyl propionate cream in skin photoageing. *Clin Exp Dermatol.* 1998;23(4):162–167. doi:10.1046/j.1365-2230.1998.00331.x
23. Leenutaphong V, Nettakul A, Rattanasuwan P. Topical isotretinoin for melasma in Thai patients: a vehicle-controlled clinical trial. *J Med Assoc Thai.* 1999;82(9):868–875.
24. Yoshimura K, Momosawa A, Aiba E, et al. Clinical trial of bleaching treatment with 10% all-trans retinol gel. *Dermatol Surg.* 2003;29(2):155–160. doi:10.1046/j.1524-4725.2003.29039.x
25. Khunger N, Sarkar R, Jain RK. Tretinoin peels versus glycolic acid peels in the treatment of Melasma in dark-skinned patients. *Dermatol Surg.* 2004;30(5):756–760. doi:10.1111/j.1524-4725.2004.30212.x
26. Watson REB, Long SP, Bowden JJ, Bastrilles JY, Barton SP, Griffiths CE. Repair of photoaged dermal matrix by topical application of a cosmetic “antiageing” product. *Br J Dermatol.* 2008;158(3):472–477. doi:10.1111/j.1365-2133.2007.08364.x
27. Ghersetich I, Troiano M, Brazzini B, Arunachalam M, Lotti T. Melasma: treatment with 10% tretinoin peeling mask. *J Cosmet Dermatol.* 2010;9(2):117–121. doi:10.1111/j.1473-2165.2010.00488.x
28. Kang HY, Valerio L, Bahadoran P, Ortonne JP. The role of topical retinoids in the treatment of pigmentary disorders: an evidence-based review. *Am J Clin Dermatol.* 2009;10(4):251–260. doi:10.2165/00128071-200910040-00005
29. Sorg O, Kasraee B, Salomon D, Saurat JH. The potential depigmenting activity of retinaldehyde. *Dermatology.* 2013;227(3):231–237. doi:10.1159/000354294
30. Truchuelo MT, Jiménez N, Jaén P. Assessment of the efficacy and tolerance of a new combination of retinoids and depigmenting agents in the treatment of melasma. *J Cosmet Dermatol.* 2014;13(4):261–268. doi:10.1111/jocd.12110
31. Rendon MI, Barkovic S. Clinical evaluation of a 4% hydroquinone + 1% retinol treatment regimen for improving melasma and photodamage in Fitzpatrick skin types III–VI. *Br J Dermatol.* 2016;15(11):1435–1441.
32. Okubo T, Oyohikawa M, Futaki K, Matsukami M, Fujii A. The inhibitory effects of 4-N-butyl-resorcinol on melanogenesis. *J Dermatol Sci.* 1995;10(1):88. doi:10.1016/0923-1811(95)93865-X
33. Kim DS, Kim SY, Park SH, et al. Inhibitory effects of 4-n-butylresorcinol on tyrosinase activity and melanin synthesis. *Biol Pharm Bull.* 2005;28(12):2216–2219. doi:10.1248/bpb.28.2216
34. Khemis A, Kaiafa A, Queille-Roussel C, Duteil L, Ortonne JP. Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial. *Br J Dermatol.* 2007;156(5):997–1004. doi:10.1111/j.1365-2133.2007.07814.x
35. Huh SY, Shin JW, Na JI, Huh CH, Youn SW, Park KC. Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial. *J Dermatol.* 2010;37(4):311–315. doi:10.1111/j.1346-8138.2010.00787.x
36. Kolbe L, Mann T, Gerwat W, et al. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. *J Eur Acad Dermatol Venereol.* 2013;27(s1):19–23. doi:10.1111/jdv.12051

37. Madan Mohan NT, Gowda A, Jaiswal AK, et al. Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma. *Clin Cosmet Invest Dermatol*. 2016;9:21–27. doi:10.2147/CCID.S89451
38. Kwon SH, Yang JH, Shin JW, Park KC, Huh CH, Na JI. Efficacy of liposome-encapsulated 4-n-butylresorcinol and resveratrol cream in the treatment of melasma. *J Cosmet Dermatol*. 2020;19(4):891–895. doi:10.1111/jocd.13080
39. Kim J, Kim J, Lee YI, Almurayshid A, Jung JY, Lee JH. Effect of a topical antioxidant serum containing vitamin C, vitamin E, and FA after Q-switched 1064-nm Nd: YAG laser for treatment of environment-induced skin pigmentation. *J Cosmet Dermatol*. 2020;19(10):2576–2582. doi:10.1111/jocd.13323
40. Polnikorn N. Treatment of refractory melasma with the MedLite C6 Q-switched Nd: YAG laser and alpha arbutin: a prospective study. *J Cosmet Laser Ther*. 2010;12(3):126–131. doi:10.3109/14764172.2010.487910
41. Morag M, Nawrot J, Siatkowski I, et al. A double-blind, placebo-controlled randomized trial of Serratulae quinquefoliae folium, a new source of  $\beta$ -arbutin, in selected skin hyperpigmentations. *J Cosmet Dermatol*. 2015;14(3):185–190. doi:10.1111/jocd.12147
42. Crocco EI, Veasey JV, Boin MF, Lellis RF, Alves RO. A novel cream formulation containing nicotinamide 4%, arbutin 3%, bisabolol 1%, and retinaldehyde 0.05% for treatment of epidermal melasma. *Cutis*. 2015;96(5):337–342.
43. Baliña LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. *Int J Dermatol*. 1991;30(12):893–895. doi:10.1111/j.1365-4362.1991.tb04362.x
44. Farshi S. Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma. *J Cosmet Dermatol*. 2011;10(4):282–287. doi:10.1111/j.1473-2165.2011.00580.x
45. Mazurek K, Pierzchała E. Comparison of efficacy of products containing azelaic acid in melasma treatment. *J Cosmet Dermatol*. 2016;15(3):269–282. doi:10.1111/jocd.12217
46. Verallo-Rowell VM, Verallo V, Graupe K, Lopez-Villafuerte L, Garcia-Lopez M. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. *Acta Derm Venereol Suppl*. 1989;143:58–61.
47. Mansouri P, Farshi S, Hashemi Z, Kasraee B. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. *Br J Dermatol*. 2015;173(1):209–217. doi:10.1111/bjd.13424
48. Lee HK, Ha JW, Hwang YJ, Boo YC. Identification of L-cysteinamide as a potent inhibitor of tyrosinase-mediated dopachrome formation and eumelanin synthesis. *Antioxidants*. 2021;10(8):1202. doi:10.3390/antiox10081202
49. Santos-Neto AG D, da Silva ÍCV, Melo CR, Santana AAM, de Albuquerque-Junior RLC. Is cysteamine use effective in the treatment of melasma? A systematic review and meta-analysis. *Dermatol Ther*. 2022;35(12):e15961. doi:10.1111/dth.15961
50. Erbil H, Sezer E, Taştan B, Arca E, Kurumlu Z. Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma. *J Dermatol*. 2007;34(1):25–30. doi:10.1111/j.1346-8138.2007.00211.x
51. Sarkar R, Garg V, Bansal S, Sethi S, Gupta C. Comparative evaluation of efficacy and tolerability of glycolic acid, salicylic mandelic acid, and phytic acid combination peels in melasma. *Dermatol Surg*. 2016;42(3):384–391. doi:10.1097/DSS.0000000000000642
52. Sahu P, Dayal S. Most worthwhile superficial chemical peel for melasma of skin of color: authors' experience of glycolic, trichloroacetic acid, and lactic peel. *Dermatol Ther*. 2021;34(1):e14693. doi:10.1111/dth.14693
53. Chaudhary S, Dayal S. Efficacy of combination of glycolic acid peeling with topical regimen in treatment of melasma. *J Drugs Dermatol*. 2013;12(10):1149–1153.
54. Lim JTE. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. *Dermatol Surg*. 1999;25(4):282–284. doi:10.1046/j.1524-4725.1999.08236.x
55. Hurley ME, Guevara IL, Gonzales RM, Pandya AG. Efficacy of glycolic acid peels in the treatment of melasma. *Arch Dermatol*. 2002;138(12):1578–1582. doi:10.1001/archderm.138.12.1578
56. Ilknur T, Biçak MU, Demirtaşoğlu M, Ozkan S. Glycolic acid peels versus amino fruit acid peels in the treatment of melasma. *Dermatol Surg*. 2010;36(4):490–495. doi:10.1111/j.1524-4725.2010.01481.x
57. Faghihi G, Shashingohar A, Siadat AH. Comparison between 1% tretinoin peeling versus 70% glycolic acid peeling in the treatment of female patients with melasma. *J Drugs Dermatol*. 2011;10(12):1439–1442.
58. Dayal S, Sahu P, Dua R. Combination of glycolic acid peel and topical 20% azelaic acid cream in melasma patients: efficacy and improvement in quality of life. *J Cosmet Dermatol*. 2017;16(1):35–42. doi:10.1111/jocd.12260
59. Tse TW. Hydroquinone for skin lightening: safety profile, duration of use and when should we stop? *J Dermatol Treat*. 2010;21(5):272–275. doi:10.3109/09546630903341945
60. Guevara IL, Pandya AG. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. *Int J Dermatol*. 2003;42(12):966–972. doi:10.1111/j.1365-4632.2003.02017.x
61. Westerhof W, Kooyers TJ. Hydroquinone and its analogues in dermatology-A potential health risk. *J Cosmet Dermatol*. 2005;4(2):55–59. doi:10.1111/j.1473-2165.2005.40202.x
62. Garcia A, Fulton JE. The combination of GA and hydroquinone or kojic acid for the treatment of melasma and related conditions. *Dermatol Surg*. 1996;22(5):443–447. doi:10.1111/j.1524-4725.1996.tb00345.x
63. Monteiro RC, Kishore BN, Bhat RM, Sukumar D, Martis J, Ganesh HK. A comparative study of the efficacy of 4% hydroquinone vs 0.75% kojic acid cream in the treatment of facial melasma. *Indian J Dermatol*. 2013;58(2):157. doi:10.4103/0019-5154.108070
64. Deo KS, Dash KN, Sharma YK, Virmani NC, Oberai C. Kojic acid vis-A-vis its combinations with hydroquinone and betamethasone valerate in melasma: a randomized, single blind, comparative study of efficacy and safety. *Indian J Dermatol*. 2013;58(4):281–285. doi:10.4103/0019-5154.113940
65. Saghaie L, Pourfarzam M, Fassihi A, Sartippour B. Synthesis and tyrosinase inhibitory properties of some novel derivatives of kojic acid. *Res Pharm Sci*. 2013;8(4):233–242.
66. Saeedi M, Eslamifard M, Khezri K. Kojic acid applications in cosmetic and pharmaceutical preparations. *Biomed Pharmacother*. 2019;110:582–593. doi:10.1016/j.biopha.2018.12.006
67. Scientific Committee on Consumer Safety. European Commission. Opinion on kojic acid; [updated June 26–27, 2012; cited December 12, 2023]. Available from: [https://ec.europa.eu/health/sites/health/files/scientific\\_committees/consumer\\_safety/docs/sccs\\_o\\_098.pdf](https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_098.pdf). Accessed April 26, 2024.
68. Mann T, Gerwat W, Batzer J, et al. Inhibition of human tyrosinase requires molecular motifs distinctively different from mushroom tyrosinase. *J Invest Dermatol*. 2018;138(7):1601–1608. doi:10.1016/j.jid.2018.01.019

69. Arrowitz C, Schoelermann AM, Mann T, Jiang LI, Weber T, Kolbe L. Effective tyrosinase inhibition by thiamidol results in significant improvement of mild to moderate melasma. *J Invest Dermatol*. 2019;139(8):1691–1698.e6. doi:10.1016/j.jid.2019.02.013
70. Roggenkamp D, Sammain A, Fürstenau M, Kausch M, Passeron T, Kolbe L. Thiamidol® in moderate-to-severe melasma: 24-week, randomized, double-blind, vehicle-controlled clinical study with subsequent regression phase. *J Dermatol*. 2021;48(12):1871–1876. doi:10.1111/1346-8138.16080
71. Philipp-Dormston WG, Vila Echagüe A, Pérez Damonte SH, et al. Thiamidol containing treatment regimens in facial hyperpigmentation: an international multi-centre approach consisting of a double-blind, controlled, split-face study and of an open-label, real-world study. *Int J Cosmet Sci*. 2020;42(4):377–387. doi:10.1111/ics.12626
72. Ebrahim HM, Said Abdelshafy A, Khattab F, Gharib K. Tranexamic acid for melasma treatment: a split-face study. *Dermatol Surg*. 2020;46(11):e102–e107. doi:10.1097/DSS.0000000000002449
73. Bala HR, Lee S, Wong C, Pandya A, Rodrigues M. Oral tranexamic acid for the treatment of melasma: a review. *Dermatol Surg*. 2018;44(6):814–825. doi:10.1097/DSS.0000000000001518
74. Janney MS, Subramaniyan R, Dabas R, Lal S, Das NM, Godara SK. A randomized controlled study comparing the efficacy of topical 5% tranexamic acid solution versus 3% hydroquinone cream in melasma. *J Cutan Aesthet Surg*. 2019;12(1):63–67. doi:10.4103/JCAS.JCAS\_40\_18
75. Kim H, Moon S, Cho S, Lee J. Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review. *Acta Derm Venereol*. 2017;97(7):776–781. doi:10.2340/00015555-2668
76. Tan AWM, Sen P, Chua SH, Goh BK. Oral tranexamic acid lightens refractory melasma. *Australas J Dermatol*. 2017;58(3):e105–e108. doi:10.1111/ajd.12474
77. Lee HC, Thng TGS, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. *J Am Acad Dermatol*. 2016;75:385–392.
78. Wu S, Shi H, Wu H, et al. Treatment of melasma with oral administration of tranexamic acid. *Aesthetic Plast Surg*. 2012;36(4):964–970. doi:10.1007/s00266-012-9899-9
79. Sahu PJ, Singh AL, Kulkarni S, Madke B, Saoji V, Jawade S. Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma. *J Cosmet Dermatol*. 2020;19(6):1456–1462. doi:10.1111/jocd.13430
80. Lueangarun S, Sirithanabadekul P, Wongwicharn P, et al. Intradermal tranexamic acid injection for the treatment of melasma: a pilot study with 48-week follow-up. *J Clin Aesthet Dermatol*. 2020;13(8):36–39.
81. Banihashemi M, Zabolinejad N, Jaafari MR, Salehi M, Jabari A. Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma. *J Cosmet Dermatol*. 2015;14(3):174–177.
82. Laothaworn V, Juntongjin P. Topical 3% tranexamic acid enhances the efficacy of 1064-nm Q-switched neodymium-doped yttrium aluminum garnet laser in the treatment of melasma. *J Cosmet Laser Ther*. 2018;20(6):320–325. doi:10.1080/14764172.2018.1427869
83. Xu Y, Ma R, Julianti J, et al. Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma: a randomized, self-controlled, split-face study. *Medicine*. 2017;96(19):e6897. doi:10.1097/MD.00000000000006897
84. Saki N, Darayesh M, Heiran A. Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial. *J Dermatol Treat*. 2018;29(4):405–410. doi:10.1080/09546634.2017.1392476
85. Tehranchinia Z, Saghi B, Rahimi H. Evaluation of therapeutic efficacy and safety of tranexamic acid local infiltration in combination with topical 4% hydroquinone cream compared to topical 4% hydroquinone cream alone in patients with melasma: a split-face study. *Dermatol Res Pract*. 2018;2018:8350317. doi:10.1155/2018/8350317
86. Budamakuntla L, Loganathan E, Suresh DH, et al. A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma. *J Cutan Aesthet Surg*. 2013;6(3):139–143. doi:10.4103/0974-2077.118403
87. Sharma R, Mahajan VK, Mehta KS, Chauhan PS, Rawat R, Shiny TN. Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study. *Clin Exp Dermatol*. 2017;42(7):728–734. doi:10.1111/ced.13164
88. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. *Cutis*. 2003;72(1):67–72.
89. Torok H, Taylor S, Baumann L, et al. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. *J Drugs Dermatol*. 2005;4(5):592–597.
90. Ferreira Cestari T, Hassun K, Sittart A, de Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. *J Cosmet Dermatol*. 2007;6(1):36–39. doi:10.1111/j.1473-2165.2007.00288.x
91. Chan R, Park KC, Lee MH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinonide acetamide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. *Br J Dermatol*. 2008;159(3):697–703. doi:10.1111/j.1365-2133.2008.08717.x
92. Gong Z, Lai W, Zhao G, et al. Efficacy and safety of fluocinonide acetamide, hydroquinone, and tretinoin cream in Chinese patients with melasma: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study. *Clin Drug Investig*. 2015;35(6):385–395. doi:10.1007/s40261-015-0292-8
93. Arellano I, Cestari T, Ocampo-Candiani J, et al. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity. *J Eur Acad Dermatol Venereol*. 2012;26(5):611–618. doi:10.1111/j.1468-3083.2011.04135.x
94. Grimes PE, Bhawan J, Guevara IL, et al. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. *J Am Acad Dermatol*. 2010;62(6):962–967. doi:10.1016/j.jaad.2009.06.067
95. Sarkar R, Bansal S, Garg VK. Chemical peels for melasma in dark-skinned patients. *J Cutan Aesthet Surg*. 2012;5(4):247–253. doi:10.4103/0974-2077.104912
96. Simmler C, Pauli GF, Chen SN. Phytochemistry and biological properties of glabridin. *Fitoterapia*. 2013;90:160–184. doi:10.1016/j.fitote.2013.07.003
97. Yokota T, Nishio H, Kubota Y, Mizoguchi M. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. *Pigment Cell Res*. 1998;11(6):355–361. doi:10.1111/j.1600-0749.1998.tb00494.x
98. Zubair S, Mujtaba G. Comparison of efficacy of topical 2% liquiritin, topical 4% liquiritin and topical 4% hydroquinone in the management of melasma. *J Pak Assoc Dermatol*. 2009;19:158–163.

99. Amer M, Metwalli M. Topical liquiritin improves melasma. *Int J Dermatol*. 2000;39(4):299–301. doi:10.1046/j.1365-4362.2000.00943.x
100. Huh CH, Seo KI, Park JY, Lim JG, Eun HC, Park KC. A randomized, double-blind, placebo-controlled trial of vitamin C iontophoresis in melasma. *Dermatology*. 2003;206(4):316–320. doi:10.1159/000069943
101. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. *Int J Dermatol*. 2004;43(8):604–607. doi:10.1111/j.1365-4632.2004.02134.x
102. Hwang S-W, Oh D-J, Lee D, Kim J-W, Park S-W. Clinical efficacy of 25% l-Ascorbic Acid (C'ensil) in the treatment of melasma. *J Cutan Med Surg*. 2009;13(2):74–81. doi:10.2310/7750.2008.07092
103. Handog EB, Galang DA, de Leon-Godinez MA, Chan GP. A randomized, double-blind, placebo-controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women. *Int J Dermatol*. 2009;48(8):896–901. doi:10.1111/j.1365-4632.2009.04130.x
104. Costa A, Silva C, Arruda L, Zaniboni M, Cordero T, Moisés T. The association of emblica, licorice, and belides is an effective alternative to hydroquinone for the clinical treatment of melasma: P3205. *J Am Acad Dermatol*. 2010;62(3):AB119.
105. Al-Niaimi F, Chiang NYZ. Topical vitamin C and the skin: mechanisms of action and clinical applications. *J Clin Aesthet Dermatol*. 2017;10(7):14–17.
106. Menon A, Eram H, Kamath PR, Goel S, Babu AMA. Split face comparative study of safety and efficacy of microneedling with Tranexamic acid versus microneedling with vitamin C in the treatment of melasma. *Indian Dermatol Online J*. 2019;11(1):41–45. doi:10.4103/idoj.IDOJ\_22\_19
107. Ismail ESA, Patsatsi A, Abd El-Maged WM, Nada EEAE. Efficacy of microneedling with topical vitamin C in the treatment of melasma. *J Cosmet Dermatol*. 2019;18(5):1342–1347. doi:10.1111/jocd.12878
108. Taylor MB, Yanaki JS, Draper DO, Shurtz JC, Coglianese M. Successful short-term and long-term treatment of melasma and postinflammatory hyperpigmentation using vitamin C with a full-face iontophoresis mask and a mandelic/malic acid skin care regimen. *J Drugs Dermatol*. 2013;12(1):45–50.
109. Sarkar R, Arora P, Garg KV. Cosmeceuticals for hyperpigmentation: what is available? *J Cutan Aesthet Surg*. 2013;6(1):4–11. doi:10.4103/0974-2077.110089
110. Lima PB, Dias JAF, Esposito ACC, Miot LDB, Miot HA. French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial. *J Eur Acad Dermatol Venereol*. 2021;35(2):502–508. doi:10.1111/jdv.16896
111. Zduńska K, Dana A, Kolodziejczak A, Rotsztejn H. Antioxidant properties of FA and its possible application. *Skin Pharmacol Phys*. 2018;31(6):332–336. doi:10.1159/000491755
112. Ichihashi M, Funasaka Y, Ohashi A, et al. The inhibitory effect of DL-alpha-tocopheryl ferulate in lecithin on melanogenesis. *Anticancer Res*. 1999;19(5A):3769–3774.
113. Funasaka Y, Komoto M, Ichihashi M. Depigmenting effect of alpha-tocopheryl ferulate on normal human melanocytes. *Pigment Cell Res*. 2003;13(Suppl. 8):170–174.
114. Tirado-Sánchez A, Santamaría-Román A, Ponce-Olivera RM. Efficacy of dioic acid compared with hydroquinone in the treatment of melasma. *Int J Dermatol*. 2009;48(8):893–895. doi:10.1111/j.1365-4632.2009.04105.x
115. Navarrete-Solis J, Castanedo-Cázares JP, Torres-álvarez B, et al. A double-blind, randomized clinical trial of niacinamide 4% versus hydroquinone 4% in the treatment of melasma. *Dermatol Res Pract*. 2011;2011:379173. doi:10.1155/2011/379173
116. Forbat E, Al-Niaimi F, Ali FR. Use of nicotinamide in dermatology. *Clin Exp Dermatol*. 2017;42(2):137–144. doi:10.1111/ced.13021
117. Wallo W, Nebus J, Leyden JJ. Efficacy of a soy moisturizer in photoaging: a double-blind, vehicle-controlled, 12-week study. *J Drugs Dermatol*. 2007;6(9):917–922.
118. Hermanns JF, Petit L, Martalo O, Piérard-Franchimont C, Cauwenbergh G, Piérard GE. Unraveling the patterns of subclinical pheomelanin-enriched facial hyperpigmentation: effect of depigmenting agents. *Dermatology*. 2000;201(2):118–122. doi:10.1159/000018473
119. Pierard G, Graf R, Gonzalez R, Cauwenbergh W. Effects of soy on hyperpigmentation in Caucasian and Hispanic populations. In: 59th Annual Meeting of the American Academy of Dermatology; March 2–7; 2001; Washington, DC.
120. Soliman MM, Ramadan SA, Bassiouny DA, Abdelmalek M. Combined trichloroacetic acid peel and topical ascorbic acid versus trichloroacetic acid peel alone in the treatment of melasma: a comparative study. *J Cosmet Dermatol*. 2007;6(2):89–94. doi:10.1111/j.1473-2165.2007.00302.x
121. Abdel-Majid EM, Helmy ER, Abdel Motaleb AA. Modified Jessner's solution combined with trichloroacetic acid 20% versus glycolic acid 70% combined with trichloroacetic acid 20% in the treatment of melasma. *Dermatol Surg*. 2021;47(5):e179–e183. doi:10.1097/DSS.0000000000002964
122. Abdel-Meguid AM, Taha EA, Ismail SA. Combined jessner solution and trichloroacetic acid versus trichloroacetic acid alone in the treatment of melasma in dark-skinned patients. *Dermatol Surg*. 2017;43(5):651–656. doi:10.1097/DSS.0000000000001036
123. Murtaza F, Bangash AR, Khushdil A, Noor SM. Efficacy of trichloro-acetic acid peel alone versus combined topical magnesium ascorbyl phosphate for epidermal melasma. *J Coll Physicians Surg Pak*. 2016;26(7):557–561.
124. Ando H, Ryu A, Hashimoto A, Oka M, Ichihashi M. Linoleic acid and alpha-linolenic acid lightens ultraviolet-induced hyperpigmentation of the skin. *Arch Dermatol Res*. 1998;290(7):375–381. doi:10.1007/s004030050320
125. Kanwar AJ, Dhar S, Kaur S. Treatment of melasma with potent topical corticosteroids. *Dermatology*. 1994;188(2):170. doi:10.1159/000247129
126. Nassar AAE, Ibrahim AM, Mahmoud AA. Efficacy and safety of intralesional steroid injection in the treatment of melasma. *J Cosmet Dermatol*. 2021;20(3):862–867. doi:10.1111/jocd.13628
127. Kirsch B, Hoesly PM, Jambusaria A, Heckman MG, Diehl NN, Sluzevich JC. Evaluating the efficacy, safety, and tolerability of the combination of tazarotene, azelaic acid, tacrolimus, and zinc oxide for the treatment of melasma: a pilot study. *J Clin Aesthet Dermatol*. 2019;12(5):40–45.
128. Adalatkhah H, Sadeghi-Bazargani H. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial. *Drug Des Devel Ther*. 2015;9:4219–4225. doi:10.2147/DDDT.S80713
129. Cohen PR. Melasma treatment: a novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor. *Med Hypotheses*. 2017;101:1–5. doi:10.1016/j.mehy.2017.01.020
130. Dhaliwal S, Rybak I, Ellis SR, et al. Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoaging. *Br J Dermatol*. 2019;180(2):289–296. doi:10.1111/bjd.16918
131. Zasada M, Budzisz E. Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments. *Postepy Dermatol Alergol*. 2019;36(4):392–397. doi:10.5114/ada.2019.87443
132. Ortonne JP. Retinoid therapy of pigmentary disorders. *Dermatol Ther*. 2006;19(5):280–288. doi:10.1111/j.1529-8019.2006.00085.x

133. Shroet B. Pharmacodynamics and pharmacokinetics of topical Adapalene. *J Am Acad Dermatol*. 1998;39(2):S17–S24. doi:10.1016/S0190-9622(98)70440-2
134. Sharquie KE, Al-Mashhadani SA, Salman HA. Topical 10% zinc sulfate solution for treatment of melasma. *Dermatol Surg*. 2008;34(10):1346–1349. doi:10.1111/j.1524-4725.2008.34287.x
135. Ni Z, Mu Y, Gulati O. Treatment of melasma with Pycnogenol®. *Phytother Res*. 2002;16(6):567–571. doi:10.1002/ptr.1085
136. Babbush KM, Babbush RA, Khachemoune A. Treatment of melasma: a review of less commonly used antioxidants. *Int J Dermatol*. 2021;60(2):166–173. doi:10.1111/ijd.15133
137. Balevi A, Ustuner P, Özdemir M. Salicylic acid peeling combined with vitamin C mesotherapy versus salicylic acid peeling alone in the treatment of mixed type melasma: a comparative study. *J Cosmet Laser Ther*. 2017;19(5):294–299. doi:10.1080/14764172.2017.1314501
138. Conforti C, Zalaudek I, Vezzoni R, et al. Chemical peeling for acne and melasma: current knowledge and innovations. *G Ital Dermatol Venereol*. 2020;155(3):280–285. doi:10.23736/S0392-0488.19.06425-3
139. Sarkar R, Arsiwala S, Dubey N, et al. Chemical peels in melasma: a review with consensus recommendations by Indian Pigmentary Expert Group. *Indian J Dermatol*. 2017;62(6):578–584. doi:10.4103/ijd.IJD\_490\_17
140. Kroon MW, Wind BS, Beek JF, et al. Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. *J Am Acad Dermatol*. 2011;64(3):516–523. doi:10.1016/j.jaad.2010.01.048
141. Massaki ABMN, Eimpunth S, Fabi SG, Guiha I, Groff W, Fitzpatrick R. Treatment of melasma with the 1927-nm fractional thulium fiber laser: a retrospective analysis of 20 cases with long-term follow-up. *Lasers Surg Med*. 2013;45(2):95–101. doi:10.1002/lsm.22100
142. Toulraki A, Galimberti MG, Pellacani G, Bencini PL. Combination of fractional erbium-glass laser and topical therapy in melasma resistant to triple-combination cream. *J Dermatol Treat*. 2014;25(3):218–222. doi:10.3109/09546634.2012.671911
143. Rho N-K. Treatment of melasma using a novel 1927 nm fractional thulium laser: a retrospective analysis of 68 Korean Patients. *Med Lasers*. 2017;6(1):10–16. doi:10.25289/ML.2017.6.1.10
144. Trivedi M, Yang F, Cho B. A review of laser and light therapy in melasma. *Int J Women's Dermatol*. 2017;3(1):11–20. doi:10.1016/j.ijwd.2017.01.004
145. Ma W, Gao Q, Liu J, et al. Efficacy and safety of laser-related therapy for melasma: a systematic review and network meta-analysis. *J Cosmet Dermatol*. 2023;22(11):2910–2924. doi:10.1111/jocd.16006
146. Choi Y-J, Nam J-H, Kim JY, et al. Efficacy and safety of a novel picosecond laser using combination of 1064 and 595 nm on patients with melasma: a prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial. *Lasers Surg Med*. 2017;49(10):899–907. doi:10.1002/lsm.22735
147. Chen Y-T, Lin E-T, Chang C-C, et al. Efficacy and safety evaluation of picosecond alexandrite laser with a diffractive lens array for treatment of melasma in asian patients by VISIA imaging system. *Photobiomodulation Photomed Laser Surg*. 2019;37(9):559–566. doi:10.1089/photob.2019.4644
148. Manuskiatti W, Yan C, Tantrapornpong P, Cembrano KAG, Techapichetvanich T, Wanitphakdeedecha R. A prospective, split-face, randomized study comparing a 755-nm picosecond laser with and without diffractive lens array in the treatment of melasma in asians. *Lasers Surg Med*. 2021;53(1):95–103. doi:10.1002/lsm.23312
149. Lin ET, Chiang HM, Lin BS, Huang YH, Chang CC. Photoaging reversibility in asian patients with melasma treated using picosecond lasers with a diffractive lens array: a 1-year prospective observational cohort study. *Dermatol Surg*. 2021;47(1):e10–e14. doi:10.1097/DSS.0000000000002405
150. Park BJ, Jung YJ, Ro YS, Chang SE, Kim JE. Therapeutic effects of new pulsed-type microneedling radiofrequency for refractory facial pigmentary disorders. *Dermatol Surg*. 2022;48(3):327–333. doi:10.1097/DSS.0000000000003367
151. Feng X, Su H, Xie J. The efficacy and safety of microneedling with topical tranexamic acid for melasma treatment: a systematic review and meta-analysis. *J Cosmet Dermatol*. 2023;23(1):33–43.
152. Mamdouh Kamal Dawaud S, Hegab DS, Mohamed El Maghraby G, Ahmad El-Ashmawy A. Efficacy and safety of topical tranexamic acid alone or in combination with either fractional carbon dioxide laser or microneedling for the treatment of melasma. *Dermatol Pract Concept*. 2023;13(3):e2023195. doi:10.5826/dpc.1303a195
153. Castanedo-Cazares JP, Hernandez-Blanco D, Carlos- Ortega B, Fuentes-Ahumada C, Torres-Alvarez B. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. *Photodermatol Photoimmunol Photomed*. 2014;30(1):35–42. doi:10.1111/phpp.12086
154. Vazquez M, Sanchez JL. The efficacy of a broad-spectrum sunscreen in the treatment of melasma. *Cutis*. 1983;32(1):92.
155. Morgado-Carrasco D, Piquero-Casals J, Granger C, Trullàs C, Passeron T. Melasma: the need for tailored photoprotection to improve clinical outcomes. *Photodermatol Photoimmunol Photomed*. 2022;38(6):515–521. doi:10.1111/phpp.12783
156. Pedroso AG, Furtado GRD, Barbosa KL. Niacinamide for the treatment of melasma: an integrative review of randomized clinical trials. *Res Soc Develop*. 2022;11(11):e198111133581. doi:10.33448/rsd-v11i11.33581

## Clinical, Cosmetic and Investigational Dermatology

Dovepress

### Publish your work in this journal

Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access, online journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. This journal is indexed on CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal>